DEA’s suspension of McKesson Corporation Retraction

Posted in Latest News on January 19, 2017.

The previous post, regarding the DEA’s suspension of McKesson Corporation’s sales of controlled substances from distribution in Florida, was found to be confusing. This suspension will impact one distribution center in Florida and impacts only the handling of hydromorphone. The Florida Department of Health and Division of Medical Quality Assurance apologizes for any confusion that may have resulted from that message. For specific details about McKesson’s agreement with the DEA, please contact the DEA. For questions about the potential impact of the sanctions in Florida, please contact the DOH’s Medical Quality Assurance.



More Latest News

Fourth Quarter Performance Report
September 2, 2022

Released for the
2021 – 2022 Fiscal Year Continue reading


Website Server Maintenance Notice
July 5, 2022

Please be aware of website server maintenance for MQA Websites beginning Friday, July 8th at 5:00PM EST. Click here for more information. Continue reading